Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gynecologic Cancers
•
Ovarian Cancer
How do you approach a young nulliparous patient desiring future fertility who presents with a complex adnexal mass and an elevated B-hCG concerning for a non-gestational choriocarcinoma?
What chemotherapy regimen would you use post-operatively?
Related Questions
How would you approach adjuvant therapy for a patient who was diagnosed with surgically staged and completely resected stage II high-grade serous ovarian cancer while she prepared for neoadjuvant chemoradiation for rectal cancer?
Given the platinum drug shortage and the recently presented NOW trial, would you consider PARP inhibitor use in place of platinum-based chemotherapy for advanced ovarian cancer?
For a patient with adenosarcoma of the ovary with high grade sarcomatous overgrowth removed intact with appropriate oncologic surgery, is there any role for radiation?
Do you personally review all imaging you order or rely judiciously on radiologist interpretation?
Do you routinely give prophylactic antibiotics/steroids for patients on MEK-inhibitors (e.g., trametinib) to prevent rash/dermatitis?
Would you prescribe vaginal estrogen cream for vaginal dryness to a patient in her 40s with a history of stage IA granulosa cell tumor?
Do you test ovarian cancer tumors for targetable biomarkers (e.g., HER2, folate receptor, MMR) at the time of primary diagnosis or at time of recurrence?
What factors do you consider when deciding between 3 versus 4 cycles of BEP for ovarian germ cell tumors?
What hormonal therapy, if any, would you offer for adjuvant treatment of stage IC ER-/PR+ low grade serous ovarian cancer?
Would you use a PARP inhibitor as treatment for recurrent platinum-sensitive ovarian cancer with a RAD51 (or other moderate-penetration HRD germline) mutation?